Generated by AI
PureTech Health plc - ADR is a biotechnology company that innovates by discovering and developing new therapies designed to address significant medical challenges. As an American Depositary Receipt (ADR), it allows US investors to gain exposure to PureTech’s shares, which are primarily traded on the London Stock Exchange. This structure facilitates the engagement of US market participants by converting the shares into a form traded domestically. The company's core focus lies in the development of advanced medicine in fields like immunology, oncology, and neuroscience, offering solutions that target biological and clinical pathways that have not been previously utilized in modern treatments. By integrating cutting-edge science with commercialization expertise, PureTech is poised to make an impact in the healthcare industry. The ADR format makes the company’s innovative efforts accessible to a broader investor base, enhancing its reach and influence in the biotechnology sector. PureTech Health plc is dedicated to advancing healthcare solutions and is a significant player in shaping the future of medicine.
Website6 Tide Street
Boston, MA, 02210
United States
The latest articles about PRTC.
BOSTON, October 26, 2026--PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026
PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year.
Summary of Dec 16's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
Summary of Dec 14's posts. Generated by AI.
Investors talking about PRTC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.